New indication
Colin Kerr
Published: Wednesday, May 1, 2019
ILUVIEN® has been approved for use in UK patients for the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).
“This indication for ILUVIEN was based on data from two three-year, double-masked, prospective sham-controlled studies, PSV-FAI-001 and PSV-FAI-005, in 282 patients with NIU-PS, randomised 2:1 (ILUVIEN:sham). Published data from the PSV-FAI-001 study have shown ILUVIEN to be superior when compared to treated sham for multiple study outcomes, including the primary outcome of recurrence of NIU-PS at six months (27.6% ILUVIEN vs 90.5% sham, p<0.001),” said a spokesman for Alimera Sciences, manufacturers of ILUVIEN.
alimerasciences.com
Latest Articles
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Picture This: Photo Contest Winners
ESCRS 2025 Refractive and Cataract Photo Contest winners.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Nutrition and the Eye: A Recipe for Success
A look at the evidence for tasty ways of lowering risks and improving ocular health.
New Award to Encourage Research into Sustainable Practices
Sharing a Vision for the Future
ESCRS leaders update Trieste conference on ESCRS initiatives.
Extending Depth of Satisfaction
The ESCRS Eye Journal Club discuss a new study reviewing the causes and management of dissatisfaction after implantation of an EDOF IOL.
Conventional Versus Laser-Assisted Cataract Surgery
Evidence favours conventional technique in most cases.